Dr. Martin Brenner, DVM, Ph.D. is Chief Executive Officer and Chief Scientific Officer of iBio ( https://ibioinc.com/team/martin-brenner-dvm-ph-d/ ), a biotech company developing the next generation of cardiometabolic and obesity medicines to promote higher quality weight loss and enhance overall metabolic health and function, as well as a pipeline of therapeutic candidates in immuno-oncology for some of the most-difficult-to-treat cancers, including solid tumors in lung, colorectal, and breast cancer, head and neck cancer, pancreatic cancer and glioblastoma, a fast-growing brain tumor.
Dr. Brenner has a strong history of success heading drug discovery and development teams at several of the world’s leading pharmaceutical companies, including AstraZeneca, Eli Lilly and Company, Pfizer Inc., and Merck Research Laboratories.
Most recently, Dr. Brenner served as the CSO at Pfenex Inc., which, using its patented Pfēnex Expression Technology® platform, created an advanced pipeline of therapeutic equivalents, vaccines, biologics and biosimilars. Pfenex was acquired by Ligand Pharmaceuticals Incorporated for approximately $516 million in October 2020.
Previously, Dr. Brenner served as the CSO at Recursion Pharmaceuticals, Inc., a company focused on accelerating drug discovery for rare diseases and diseases with high unmet medical need.
Prior to his time at Recursion, Dr. Brenner was Vice President and Head of Research & Early Development at Stoke Therapeutics, Inc., a biotechnology company using antisense oligonucleotides to increase gene expression for the treatment of rare diseases.
Prior to Stoke, Dr. Brenner was Executive Director at Merck, where he built a biotech unit from scratch, focusing his team’s research on diabetes and nonalcoholic steatohepatitis (NASH).
Earlier in his career, Dr. Brenner was the Senior Director and Head of cardiovascular, renal, and metabolism (CVRM) biosciences at AstraZeneca.
In addition, Dr. Brenner was an Associate Research Fellow at Pfizer where he led the islet biology and in vivo pharmacology in the CVMED Target Exploration Unit before assuming the role of Head of the Insulin Resistance Group.
Dr. Brenner has a DVM, Veterinary Medicine, Ludwig-Maximilians-Universität München and a Ph.D., Pharmacology Tieraerztliche Hochschule Hannover.
#MartinBrenner #iBio #Cardiometabolic #Obesity #Medicines #WeightLoss #MetabolicHealth #ImmunoOncology #GLP1 #BispecificAntibodies #ArtificialIntelligence #TransformingGrowthFactorBeta #Myostatin #ActivinA #ActivinE #MuscleMass #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research
Popular Podcasts
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
Boysober
Have you ever wondered what life might be like if you stopped worrying about being wanted, and focused on understanding what you actually want? That was the question Hope Woodard asked herself after a string of situationships inspired her to take a break from sex and dating. She went "boysober," a personal concept that sparked a global movement among women looking to prioritize themselves over men. Now, Hope is looking to expand the ways we explore our relationship to relationships. Taking a bold, unfiltered look into modern love, romance, and self-discovery, Boysober will dive into messy stories about dating, sex, love, friendship, and breaking generational patterns—all with humor, vulnerability, and a fresh perspective.
Dateline NBC
Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com